TY - JOUR T1 - COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.210480 SP - jrheum.210480 AU - Bonnie L. Bermas AU - Milena Gianfrancesco AU - Helen L. Tanner AU - Andrea M. Seet AU - Mathia C. Aguiar AU - Nasra K. Al Adhoubi AU - Samar Al Emadi AU - Bernardo M. Cunha AU - Rachael Flood AU - Daria A. Kusevich AU - Eoghan M. McCarthy AU - Naomi J. Patel AU - Eric Ruderman AU - Sebastian E. Sattui AU - Savino Sciascia AU - Faizah Siddique AU - Maria O. Valenzuela-Almada AU - Leanna M. Wise AU - Angus B. Worthing AU - JoAnn Zell AU - Suleman Bhana AU - Wendy Costello AU - Ali Duarte-Garcia AU - Rebecca Grainger AU - Laure Gossec AU - Jonathan S. Hausmann AU - Kimme Hyrich AU - Saskia Lawson-Tovey AU - Jean W. Liew AU - Emily Sirotich AU - Jeffrey A. Sparks AU - Paul Sufka AU - Zachary S. Wallace AU - Pedro M. Machado AU - Anja Strangfeld AU - Megan E.B. Clowse AU - Jinoos Yazdany AU - Philip C. Robinson Y1 - 2021/09/01 UR - http://www.jrheum.org/content/early/2021/10/10/jrheum.210480.abstract N2 - Objective To describe coronavirus disease 2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection. Methods Since March 2020, the COVID-19 Global Rheumatology Alliance has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers. Results We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24–45 years. Rheumatic disease diagnoses included rheumatoid arthritis (n = 9), systemic lupus erythematosus (n = 9), psoriatic arthritis/other inflammatory arthritides (n = 8), and antiphospholipid syndrome (n = 6). Most had a term birth (16/22), with 3 preterm births, 1 termination, and 1 miscarriage; 1 woman had yet to deliver at the time of report. One-quarter (n = 10/39) of pregnant women were hospitalized following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalized); no patients died. The majority did not receive specific medication treatment for their COVID-19 (n = 32/39, 82%), and 7 patients received some combination of antimalarials, colchicine, anti–interleukin 1β, azithromycin, glucocorticoids, and lopinavir/ritonavir. Conclusion Women with rheumatic diseases who were pregnant at the time of COVID-19 had favorable outcomes. These data have limitations due to the small size and methodology; however, they provide cautious optimism for pregnancy outcomes for women with rheumatic disease particularly in comparison to the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19. ER -